



28 June 2023

ASX ANNOUNCEMENT

ImpediMed Updates Board for Growth in Oncology

Board Changes:

- **Dr Michael Seiden and Daniel Sharp appointed as Non-executive Directors**
- **Dr Robert Graham, AO to resign**

The Board of ImpediMed Limited (ASX:IPD) (**ImpediMed, Company**) is pleased to announce the appointment of Michael Seiden, MD, PhD and Daniel Sharp, CFA as independent Non-executive Directors, effective 1 July 2023.

Dr Seiden is a Board-Certified Medical Oncologist who brings a broad background of leadership positions across the cancer care and business ecosystems. His previous experience includes serving as president of US Oncology Network, a McKesson owned company that includes the largest collection of community-based oncology care practices in the United States. He also served as CEO and President of Fox Chase Cancer Center, a National Cancer Institute designated research center as well as a founding member of the National Comprehensive Cancer Network (NCCN®).

"I am very familiar with SOZO from my time at US Oncology and know the impact it has on improving the quality of life of patients. I am thrilled to help the Company further embed this novel technology as the standard of care for cancer patients and beyond," commented Dr Seiden.

Mr Sharp brings a wealth of capital markets expertise to the board. Until his retirement in 2020, Mr Sharp was responsible for Equity Capital Market banking transactions and corporate advisory services in the life sciences and healthcare sector at Canaccord Genuity Australia. He currently serves as a Non-executive Director at Alcideon Group (ASX:ALC) and Botanix Pharmaceuticals (ASX:BOT) and is a member of the Investment Committee for the Baker Heart and Diabetes Institute Foundation.

"It is exciting to see the growth trajectory of ImpediMed unfolding on the back of the inclusion of the Company's technology in the NCCN Guidelines. I am excited to combine my corporate advisory and capital markets experience with my deep understanding of the business to help guide the Company forward," commented Mr Sharp.

Commenting on the appointments, ImpediMed's Chair Don Williams said, "Building on the momentum of the Company's recent milestone achievements, we are fortunate to welcome two new board members whose expertise aligns with our business goals and objectives. Dr Seiden brings a deep understanding of oncology both regarding patient care and bringing new technologies to market. Mr Sharp's knowledge of the healthcare and capital markets will be a valuable resource as management and the board navigate the growth of the Company."

Also today, the Company announces that Dr Robert Graham has resigned as a Non-Executive Director, effective 30 June 2023. Dr Graham has served on the Board since 2017. Board chair Mr. Williams said, "On behalf of the Board and Management I would like to extend our gratitude to Dr Graham for his exceptional contribution to the Company during a period of significant accomplishment. We wish him continued success in the future".

Approved for release by the Chair of ImpediMed Limited, Mr Donald Williams.

Contact Details

Donald Williams

T: +1-760-585-2146

E: dwilliams@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO[®] Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines[®]) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex[®], ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.